ARCH Venture Partners IX, LLC bought $12M of LYEL
owner at Lyell Immunopharma, Inc.. 488,090 shares at an average of $25.61, traded Mar 6, 2026, filed Mar 9, 2026.
Score components
- +12Role10% owner
- +25Trade size$12.5M at market
- +10Relative to holdingsHoldings up 52%
- +8Price context42% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001012975-26-000235, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | POpen-market purchase Common Stockindirect: See footnote | +488,090 | $25.61 | $12M | 1,426,528 | Mar 9, 2026 |
Related signals
Other insiders at Lyell Immunopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LYELsell Lyell Immunopharma, Inc. | David Shook Chief Medical Officer | $6,350 500 shares | -2% | |
| 58Moderate | Lyell Immunopharma, Inc. | ARCH Venture Fund XIII, L.P. owner | $12M 488,090 shares | +52% | |
| 15Weak | LYELsell Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $5,872 254 shares | -2% | |
| 28Weak | LYELsell Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $74k 2,072 shares | -22% | |
| 30Weak | Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $3,848 239 shares | -3% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $1,531 95 shares | -1% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $2,230 138 shares | -1% | |
| 40Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $6,637 412 shares | -1% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $11k 1,004 shares | -6% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $15k 1,453 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.